Coherus Oncology reports interim tagmokitug data showing high response rates in esophageal cancer
Coherus Oncology announced interim results from its Phase 1b TREGCHECK program evaluating tagmokitug with toripalimab in esophageal squamous cell carcinoma. In first‑line patients the confirmed overall response rate was 75% and later rose to 89% after additional responses, with a 100% response among PD‑L1‑positive cases. In the second‑line cohort the confirmed response rate was 16.7% with a clinical benefit rate of 33.3% and a median progression‑free survival of 5.5 months. The company said it will broaden enrollment in both cohorts.
Why it matters
The company indicated that the data support expanding the ESCC studies and will be discussed with the FDA, which could accelerate regulatory pathways and affect the stock price, as shares fell 9.48% in pre‑market trading after the release.
Key facts
- 1First‑line ESCC interim confirmed overall response rate was 75% among eight evaluable patients. rttnews.com
- 2Subsequent confirmations increased the first‑line response rate to 89%. rttnews.com
- 3In PD‑L1‑positive first‑line patients the confirmed response rate was 100%. rttnews.com
- 4Second‑line ESCC 700 mg cohort confirmed response rate was 16.7%. rttnews.com
- 5Second‑line ESCC 700 mg cohort clinical benefit rate was 33.3%. rttnews.com
- 6Median progression‑free survival in the second‑line cohort was 5.5 months. finance.yahoo.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.